These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37272931)

  • 1. Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
    Hong L; Wang X; Zheng L; Wang S; Zhu G
    Cancer Chemother Pharmacol; 2023 Jul; 92(1):71-81. PubMed ID: 37272931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L; Zhang Q; Du L; Zheng F
    Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated macrophages promote the metastasis of ovarian carcinoma cells by enhancing CXCL16/CXCR6 expression.
    Hong L; Wang S; Li W; Wu D; Chen W
    Pathol Res Pract; 2018 Sep; 214(9):1345-1351. PubMed ID: 30049511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L; Zhang B; Li W
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
    Ma H; Shen L; Yang H; Gong H; Du X; Li J
    IUBMB Life; 2021 Jan; 73(1):108-117. PubMed ID: 33205540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
    Wang G; Li L; Li Y; Zhang LH
    Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.
    Liu M; Peng J
    Comput Math Methods Med; 2022; 2022():2318170. PubMed ID: 35651928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
    Sheng H; Wang X
    Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
    Zhang J; Bai HJ
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
    [No Abstract]   [Full Text] [Related]  

  • 13. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
    Wei L; He W; Zhao H; Zhao P
    Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
    Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
    Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
    Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
    Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
    Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
    Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.